Canadian Treat and Extend Analysis Trial With Ranibizumab

Inclusion Criteria: * Infomed consent, * Male and Female, 50 years of age or older * Diagnosis of treatment-naive CNV secondary to age-related macular degeneration(AMD) in the study eye, * BCVA score between 78 and 19 letters inclusive, Exclusion Criteria: * Patients with structural foveal damage in the study eye, * Patients with confounding severe oculare diseases, * Patients with suspicion of ( Polypoidal Choroidal Vasculapathy PCV) in the study eye, * Patients with active or suspected or periocular infections in either eye or active intraocular inflammation in either eye, * Patients who had previous subfoveal laser photocoagulation in the study eye or history of vitrectomy surgery in the study eye, * Patients who had any prior treatment in the study eye, e.g., with Visudyne\*, Avastin\*, prior Ranibizumab treatment, Ozurdex\*, external radiation therapy, transpupillary thermotherapy (TTT), or any intravitreal injection, * Patients with a known sensitivity to Ranibizumab or any component of its formulation, * Patients who have used any investigational agent in the last 30 days, * Concurrent participation in a clinical trial or within 30 days prior to enrollment, * Patients having received systemic treatment with any other anti-vascular endothelial growth factor (VEGF) therapy ≤ 60 days prior to enrollment * Patients with physical or mental disabilities that prevent accurate vision testing, * Patients physically unable to tolerate intravenous fluorescein angiography, * Pregnant or breastfeeding female patients, * Any patient with recent history of new onset cardiac disease or thromboembolic central nervous system (CNS) event (within 12 months of Baseline Visit), * Patients with any other condition which, in the opinion of the Investigator, would require treatment that would significantly impact the treatment assessments during this study.